€ million |
|
Note |
|
2024 |
|
2023 |
|---|---|---|---|---|---|---|
Profit after tax |
|
|
|
2,786 |
|
2,834 |
Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Net defined benefit liability |
|
|
|
|
|
|
Changes in remeasurement |
|
|
|
179 |
|
-236 |
Tax effect |
|
|
|
-89 |
|
48 |
Changes recognized in equity |
|
|
|
90 |
|
-187 |
Equity instruments |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
37 |
|
158 |
Tax effect |
|
|
|
-6 |
|
2 |
Changes recognized in equity |
|
|
|
30 |
|
160 |
|
|
|
|
121 |
|
-28 |
Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
92 |
|
98 |
Reclassification to profit or loss |
|
|
|
-149 |
|
-95 |
Reclassification to assets |
|
|
|
– |
|
– |
Tax effect |
|
|
|
5 |
|
-5 |
Changes recognized in equity |
|
|
|
-52 |
|
-2 |
Cost of cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
– |
|
-17 |
Reclassification to profit or loss |
|
|
|
-2 |
|
22 |
Reclassification to assets |
|
|
|
– |
|
– |
Tax effect |
|
|
|
– |
|
– |
Changes recognized in equity |
|
|
|
-2 |
|
5 |
Currency translation difference |
|
|
|
|
|
|
Changes taken directly to equity |
|
|
|
1,444 |
|
-1,003 |
Reclassification to profit or loss |
|
|
|
-15 |
|
-15 |
Changes recognized in equity |
|
|
|
1,429 |
|
-1,018 |
|
|
|
|
1,375 |
|
-1,015 |
Other comprehensive income |
|
|
|
1,496 |
|
-1,043 |
Comprehensive income |
|
|
|
4,282 |
|
1,791 |
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany |
|
|
|
4,272 |
|
1,783 |
thereof: attributable to non-controlling interests |
|
|
9 |
|
8 |